Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

ABSTRACT
The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵# Joint first authors
Subject Area
- Biochemistry (7780)
- Bioengineering (5671)
- Bioinformatics (21250)
- Biophysics (10565)
- Cancer Biology (8164)
- Cell Biology (11915)
- Clinical Trials (138)
- Developmental Biology (6740)
- Ecology (10388)
- Epidemiology (2065)
- Evolutionary Biology (13845)
- Genetics (9695)
- Genomics (13058)
- Immunology (8129)
- Microbiology (19970)
- Molecular Biology (7839)
- Neuroscience (42991)
- Paleontology (318)
- Pathology (1276)
- Pharmacology and Toxicology (2257)
- Physiology (3350)
- Plant Biology (7208)
- Synthetic Biology (2000)
- Systems Biology (5529)
- Zoology (1126)